XtalPi forecasts first annual profit after 193% revenue surge

Profit turn in sight

XtalPi (晶泰科技) said it expects to post its first annual profit in 2025, projecting net income of at least 100 million yuan (US$14.5 million) after a year of rapid top-line growth, according to a filing with the Hong Kong stock exchange. The Shenzhen-based AI drug researcher flagged a swing from an estimated 2024 net loss of about 1.5 billion yuan. Its shares fell 2% to HK$9.54 on Tuesday before the profit alert was released. A turning point—or a one-off lift?

Numbers behind the swing

The company attributed the improvement to a substantial revenue increase, reporting at least 780 million yuan for the year ended December, nearly 193% higher than a year earlier. It also cited narrowing losses in its core intelligent robotics and drug discovery operations. Gains on financial assets are expected to exceed 500 million yuan, bolstering overall earnings, the filing said. That mix raises a key question for investors: how much of future profitability will come from operations versus market-driven investment income?

Context: China’s AI drug race

XtalPi develops AI-driven platforms and automated robotics to accelerate drug discovery—part of a broader push in China to apply machine learning and lab automation to pharmaceutical R&D. For Western readers, the company sits alongside a global cohort of AI-first biotech players vying to shorten timelines and cut costs in early-stage research. Hong Kong has positioned itself as a capital-raising venue for such firms, though trading can be volatile as companies transition from heavy R&D spend to commercial revenues.

Market and policy backdrop

China’s AI and biotech sectors operate amid shifting geopolitical currents, including US export controls on advanced semiconductors used to train AI models and power robotics, as well as heightened scrutiny of cross-border research. While domestic pharma outsourcing and digital R&D demand remain supportive, these policy headwinds could influence cost structures and adoption. For XtalPi, the path to sustained profitability will hinge on converting its AI and robotics stack into recurring, higher-margin contracts—rather than relying on investment windfalls.